KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBT: 2017-2025

Historic EBT for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$15.4 million.

  • Aquestive Therapeutics' EBT fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.61%. This contributed to the annual value of -$44.2 million for FY2024, which is 479.03% down from last year.
  • Aquestive Therapeutics' EBT amounted to -$15.4 million in Q3 2025, which was down 14.01% from -$13.5 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year EBT high stood at $8.1 million for Q1 2023, and its period low was -$28.9 million during Q4 2021.
  • Moreover, its 3-year median value for EBT was -$11.5 million (2024), whereas its average is -$9.4 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 429.86% in 2021, then skyrocketed by 161.03% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' EBT (Quarterly) stood at -$28.9 million in 2021, then soared by 57.33% to -$12.4 million in 2022, then soared by 35.15% to -$8.0 million in 2023, then crashed by 113.10% to -$17.1 million in 2024, then tumbled by 34.21% to -$15.4 million in 2025.
  • Its EBT was -$15.4 million in Q3 2025, compared to -$13.5 million in Q2 2025 and -$22.9 million in Q1 2025.